Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
Explore this paper's citation graph
- Type
- article
- Published
- 2018-08-20
- Cited by
- 29
- References
- 49
- Access
- Open access
- OpenAlex
- https://openalex.org/W2888433054
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:52097121
Keywords
Clusterin, Biomarker, Internal medicine, Alzheimer's Disease Neuroimaging Initiative, Apolipoprotein E
References
- Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays
- Finite Mixture Models
- Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
- Finite Mixture Models
- Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
- Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort
- The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
- Adjusting for multiple testing--when and how?
- Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients
- Plasma clusterin and the risk of Alzheimer disease.
- Replication of CLU, CR1 and PICALM associations with Alzheimer’s disease
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
- Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
- The role of clusterin in amyloid-β associated neurodegeneration
- Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
- Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease
- Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’
- Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: the relation to Alzheimer’s disease pathology
- Plasma β-amyloid in Alzheimer’s disease and vascular disease
Cited by
- Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease
- Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions.
- A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease.
- Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project.
- Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease
- Utility of Animal Models to Understand Human Alzheimer’s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals
- A Longitudinal Examination of Plasma Neurofilament Light and Total Tau for the Clinical Detection and Monitoring of Alzheimer’s Disease
- DIET INFLUENCES PERIPHERAL AMYLOID β METABOLISM: A ROLE FOR CIRCULATING INSULIN-LIKE GROWTH FACTOR I
- A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma
- Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
- Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
- Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer’s disease
- Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease
- Memory Clinics and Day Care Centers in Thessaloniki, Northern Greece: 30 Years of Clinical Practice and Experience
- Circulating insulin-like growth factor I is involved in the effect of diet on peripheral amyloid β clearance
- Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
- Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease:insights from clinical trials with secretase inhibitors and monoclonal antibodies.
- Forecasting individual progression trajectories in Alzheimer’s disease
- Understanding ethnic diversity in open dementia neuroimaging datasets
Related papers
- Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease.
- Rev-ERBα Modulates Hyperoxia-induced Trans-differentiation of Lipofibroblasts in the Neonatal Mouse Lung
- Longitudinal analysis of APOE-ε4 genotype with the logical memory delayed recall score in Alzheimer’s disease
- Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
- P1–256: APOE genotype by gender interaction revealed in CSF biomarkers and clinical conversion rates in the ADNI database
- Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status
- Neuropathology-based APOE genetic risk score better quantifies Alzheimer’s risk
- Regulating effect of CBF on memory in cognitively normal older adults with different ApoE genotype: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)